glp-1 alzheimer's disease Glucagon-like peptide-1 medicines in neurological and psychiatric disorders: Cell Reports Medicine Could GLP‑1 Weight‑Loss Drugs Help

Compounded medications are not reviewed or approved by the FDA as finished products and have not undergone FDA review for safety, effectiveness, or quality

It can affect even very young people

Here is how it compares to what you already tried

What constitutes unresponsive: Clinically, per manufacture, a patient should not be considered as unresponsive to therapy until less than 5% weight loss over the course of 3 months of GLP1/GIP medication at prescribed dose has been established

This is a particularly common issue in winter

When the MCD enzyme is defective, it can lead to abnormal levels of malonyl CoA, which in turn can impact brain CPT1 and contribute to abnormal brain development